AL
ALTHX.PA Theranexus SA
- Market cap
- EUR 46.4M
- P/E
- -
- P/B
- 15.58x
- ROE
- -13.5%
- Dividend yield
- -
- Fundamental score
- 0.8/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is ALTHX.PA undervalued?
Graham numberThe Graham number of Theranexus SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Theranexus SA fundamental analysis
3 of 11 checks passedROE 0/2
The stock's ROE indicates a negative return (-72.86%) on shareholders' equity, suggesting poor financial performance.
ROA 0/2
The stock's ROA (-52.87%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.
PBV 1/2
The stock's PBV ratio (1.09x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.
DER 1/2
The stock maintains a fair debt to equity ratio (85%), indicating a reasonable balance between the money it owes and the ownership it possesses.
Revenue Growth 0/2
Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.
Net Profit Growth 0/2
Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.
Assets Growth 0/2
Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.
Graham Number 1/1
The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.
Dividend Growth 0/2
The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.
Dividend 0/2
Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.
Buffet Intrinsic Value 0/1
The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Theranexus SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Theranexus SA
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for rare neurological disease, as well as TX01 for the treatment of Gaucher disease and Niemann-Pick type C diseases. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pha…
Full company profileTheranexus SA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Theranexus SA annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 90.6K | 148K | 111K | 564K | 295K | 602.00 | 415K | 296K | 2.28M | 0.00 | 13.0M |
| Gross Profit | -1.35M | -1.33M | -6.57M | -6.74M | -5.31M | -8.82M | 82.9K | -4.64M | -334K | -109K | 4.36M |
| Operating Income | -2.06M | -2.72M | -7.10M | -7.94M | -6.39M | -9.51M | -6.26M | -7.64M | -4.81M | -10.2M | -3.06M |
| EBITDA | -2.04M | -2.69M | -6.94M | -7.36M | -5.33M | -8.67M | -5.93M | -7.39M | -2.53M | -10.1M | -2.83M |
| Net Income | -1.59M | -2.11M | -5.30M | -5.58M | -4.80M | -8.15M | -6.57M | -6.83M | -1.77M | -3.00M | -402K |
| EPS | -1.79 | -0.68 | -1.70 | -1.55 | -1.18 | -1.66 | -1.23 | -0.88 | -0.21 | -0.22 | -0.03 |
| Balance Sheet | |||||||||||
| Total Assets | 2.88M | 20.4M | 18.8M | 15.4M | 17.5M | 16.9M | 12.1M | 7.24M | 3.74M | 10.5M | 22.6M |
| Total Liabilities | 2.79M | 1.66M | 5.44M | 5.39M | 7.19M | 6.71M | 6.33M | 5.02M | 5.40M | 7.64M | 19.7M |
| Shareholders' Equity | 89.9K | 18.7M | 12.9M | 9.44M | 8.72M | 8.72M | 5.73M | 2.22M | -1.66M | 1.99M | 2.98M |
| Cash & Short-term Investments | 1.50M | 18.2M | 15.2M | 9.45M | 11.2M | 12.5M | 9.11M | 4.90M | 967K | 7.77M | 17.5M |
| Total Debt | 2.10M | 533K | 4.15M | 3.47M | 6.50M | 6.46M | 6.17M | 3.64M | 2.87M | 2.88M | 2.59M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.47M | -1.89M | -5.60M | -5.07M | -5.68M | -6.25M | -5.37M | -6.36M | -3.37M | -884K | 39.8M |
| Capital Expenditure | 169K | 149K | 329K | 2.11M | 252K | 151K | 41.2K | 43.6K | 32.7K | 56.1K | 605K |
| Free Cash Flow | -1.64M | -2.04M | -5.93M | -7.18M | -6.00M | -6.40M | -5.41M | -6.40M | -3.40M | -940K | 39.2M |
| Ratios | |||||||||||
| ROE | -1,766.0% | -11.3% | -41.2% | -59.1% | -55.0% | -93.4% | -114.6% | -307.4% | - | -151.2% | -13.5% |
| ROA | -55.1% | -10.4% | -28.1% | -36.3% | -27.5% | -48.3% | -54.5% | -94.3% | -47.2% | -28.5% | -1.8% |
| Net Profit Margin | -1,752.1% | -1,430.6% | -4,778.4% | -989.6% | -1,628.5% | -1,353,889.4% | -1,582.8% | -2,304.2% | -77.3% | - | -3.1% |
| Debt to Equity | 23.41x | 0.03x | 0.32x | 0.37x | 0.75x | 0.74x | 1.08x | 1.64x | - | 1.45x | 0.87x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Theranexus SA dividends
Theranexus SA has not paid dividends in the last 9 fiscal years.
Last stock split: 779:749 on Oct 27, 2025.
Who owns Theranexus SA
- Insiders 12.84%
- Institutions 19.74%
- Public & others 67.42%
- Shares outstanding 14.5M
- Free float 11.6M
Theranexus SA company profile
- Company name
- Theranexus SA
- Ticker
- ALTHX.PA
- ISIN
- FR0013286259
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 12
- Fiscal year end
- December
- Address
- 60, Avenue Rockefeller, Lyon, France, 69008
- Phone
- 33 1 88 89 70 31
- Website
- theranexus.com
About Theranexus SA
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for rare neurological disease, as well as TX01 for the treatment of Gaucher disease and Niemann-Pick type C diseases. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonyme in September 2025. The company was founded in 2013 and is headquartered in Lyon, France.
Theranexus SA management
6- Mr. Mathieu CharvériatCo-Founder, Scientific Director, CEO & Chairman
- Mr. Franck MouthonCo-Founder & Director
- Mr. Julien VeysDeputy CEO, COO & Director
- Ms. Christine PlacetAdministrative & Financial Director · born 1963
- Ms. Francoise Vincent-LarrodeDirector of Human Resources
- Ms. Marie SebilleChief Medical Officer